Occult Hepatitis C Virus Infection among Hemodialysis Patients: An Iranian Experience

Sedigheh Taherpour1, Davod Javanmard1,2, Masood Ziaee1

  • 1Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Archives of Iranian Medicine
|September 27, 2020
PubMed

Insights

Occult hepatitis C virus (HCV) infection is present in 1.6% of chronic hemodialysis patients in Iran. Molecular testing is crucial for early diagnosis and treatment of occult HCV infection in this high-risk population.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Nephrology

Background:

  • Patients undergoing chronic hemodialysis (CHD) face a high risk of hepatitis C virus (HCV) infection.
  • The prevalence and impact of occult HCV infection (OCI) in CHD patients remain unclear.
  • This study investigates the molecular detection of OCI in Iranian CHD patients.

Purpose of the Study:

  • To assess the prevalence of occult HCV infection (OCI) in patients undergoing chronic hemodialysis (CHD) in Iran.
  • To evaluate the utility of molecular methods for detecting OCI in this vulnerable population.
  • To identify HCV genotypes in OCI cases.

Main Methods:

  • 120 CHD patients in South Khorasan, Iran, were enrolled.
  • HCV-RNA was detected in serum and peripheral blood mononuclear cells (PBMCs) using semi-nested PCR.
  • Viral load quantification and HCV genotyping (including genotype 1a) were performed.

Main Results:

  • No HCV-RNA was detected in serum samples.
  • OCI was detected in 1.6% of PBMC samples (2/120).
  • OCI cases were younger, and viral loads were very low (mean 49 IU/mL in one case).

Conclusions:

  • A notable risk of occult HCV infection exists in Iranian chronic hemodialysis patients.
  • Low viral loads in OCI necessitate sensitive molecular diagnostics for timely detection.
  • Early diagnosis and treatment of OCI are essential, especially with the availability of direct-acting antivirals (DAA).
Abstract

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
377
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
824
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
125